2030 年亚太地区癫痫药物市场预测 - 区域分析 - 按治疗和配销通路

2022年亚太地区癫痫药物市值为21.9872亿美元，预计2030年将达到31.4344亿美元；预计2022年至2030年复合年增长率为4.6%。

老年人数量的增加推动了亚太地区癫痫药物市场的发展

预计未来几年癫痫药物市场的许多专利将到期。它可能会增加仿製药的渗透率，以减少医疗费用。这将为其他市场参与者创造更多机会。以下提到的是一些在未来几年内专利即将到期的药物。

公司专利 专利有效期限 成分处理

住友製药公司 US9206135 2026年4月21日 醋酸艾斯利卡西平 部分发作性癫痫发作

葛兰素史克 US7919115 2029 年 1 月 4 日 拉莫三嗪 癫痫

Ucb Inc USRE38551 2022 年 3 月 17 日拉科酰胺癫痫与局部发作癫痫

SK Biopharmaceuticals US7598279 2027 年 10 月 30 日 CENOBAMATE 局部性癫痫

SUPERNUS PHARMS US8877248 2027 年 11 月 托吡酯癫痫缓释製剂

SUPERNUS PHARMS US9555004 2027 年 11 月 托吡酯癫痫缓释製剂

SUPERNUS PHARMS US10314790 2027 年 11 月 托吡酯癫痫缓释製剂

SUPERNUS PHARMS US8663683 2027 年 11 月 托吡酯癫痫缓释製剂

SUPERNUS PHARMS US9622983 2027 年 11 月 托吡酯癫痫缓释製剂

SUPERNUS PHARMS US8298580 2027 年 11 月 托吡酯癫痫缓释製剂

SUPERNUS PHARMS US8992989 2027 年 11 月 托吡酯癫痫缓释製剂

SUPERNUS PHARMS US8889191 2027 年 11 月 托吡酯癫痫缓释製剂

SUPERNUS PHARMS US9549940 2027 年 11 月 托吡酯癫痫缓释製剂

SUPERNUS PHARMS US8298576 2028 年 4 月 托吡酯癫痫缓释製剂

亚太地区癫痫药物市场概况

根据中国、日本、印度、澳洲、韩国和亚太其他地区分析了亚太地区癫痫药物市场。根据世界卫生组织（WHO）报告，癫痫在发展中国家比已开发国家更为常见，盛行率分别为6.1%和5.0%。中国是世界上人口最多的国家，也是神经系统疾病患者最多的国家。根据疾病预防控制中心统计，在我国，活动性癫痫的盛行率为0.48%～8.5%；中国大陆约有900万癫痫患者，其中三分之二是儿童。约 30% 的癫痫患者无法使用目前市面上贩售的 AED 控制癫痫发作；因此，这种疾病的医疗需求显着未被满足。

此外，该国的药品批准正在推动市场成长。例如，2021年8月，卫材株式会社获得了抗癫痫药物（AED）Fycompa的两项额外批准，作为「部分性癫痫发作的单一疗法」和「部分性癫痫发作的儿科适应症的辅助治疗/单一疗法」。国家药品监督管理局发布的《中国四岁及以上癫痫患者癫痫发作的情况》。

亚太地区癫痫药物市场收入及 2030 年预测（百万美元）

亚太地区癫痫药物市场细分

亚太地区癫痫药物市场按治疗、配销通路和国家细分。

根据治疗，亚太地区癫痫药物市场分为第一代抗癫痫药物、第二代抗癫痫药物和第三代抗癫痫药物。 2022年，第三代抗癫痫药物占最大份额。

从配销通路来看，亚太地区癫痫药物市场分为医院药局、零售药局等。 2022年，医院药局部门占最大份额。

依国家/地区划分，亚太地区癫痫药物市场分为中国、日本、印度、澳洲、韩国和亚太地区其他地区。 2022年，中国在亚太癫痫药物市场占据主导地位。

雅培实验室、阿尔肯实验室有限公司、葛兰素史克公司、诺华公司、辉瑞公司、赛诺菲公司和梯瓦製药工业有限公司是亚太地区癫痫药物市场上的一些领先公司。

目录

第 1 章：简介

第 2 章：执行摘要

• 重要见解

第 3 章：研究方法

• 覆盖范围
• 二次研究
• 初步研究

第 4 章：癫痫药物市场格局

• 概述

第 5 章：亚太地区癫痫药物市场 - 主要产业动态

• 市场驱动因素
  • 癫痫盛行率不断上升
  • 老年人口数量不断增加
• 市场限制
  • 治疗产品的召回
• 市场机会
  • 几种癫痫药物专利即将到期
• 未来的趋势
  • 增加产品批准
• 影响分析

第 6 章：癫痫药物市场 - 亚太市场分析

• 概述
• 亚太地区癫痫药物市场收入，2022 - 2030

第 7 章：亚太地区癫痫药物市场 - 收入和 2030 年预测 - 按治疗方法

• 概述
• 2022 年和 2030 年亚太地区癫痫药物市场收入份额（按治疗方法）（%）
• 第一代抗癫痫药
• 第二代抗癫痫药
• 第三代抗癫痫药

第 8 章：亚太地区癫痫药物市场 - 2030 年收入和预测 - 按配销通路

• 概述
• 2022 年及 2030 年亚太地区癫痫药物市场收入份额（按配销通路）（%）
• 医院药房
• 零售药局
• 其他的

第 9 章：亚太地区癫痫药物市场 - 2030 年收入与预测 - 国家分析

• 中国
• 日本
• 印度
• 澳洲
• 韩国
• 余下的

第 10 章：癫痫药物市场-产业格局

• 概述
• 癫痫药物市场的成长策略
• 无机成长策略
  • 概述
• 有机成长策略
  • 概述

第 11 章：公司简介

• Novartis AG
• Pfizer Inc
• GSK Plc
• Abbott Laboratories
• Sanofi SA
• Teva Pharmaceutical Industries Ltd
• Alkem Laboratories Ltd

第 12 章：附录

The Asia Pacific epilepsy drugs market was valued at US$ 2,198.72 million in 2022 and is expected to reach US$ 3,143.44 million by 2030; it is estimated to grow at a CAGR of 4.6% from 2022 to 2030.

Increasing Number of Elderly People Fuels the Asia Pacific Epilepsy Drugs Market

Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.

Company Patent Patent Expiration Date Ingredient Treatment

Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy

GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy

Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures

SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies

SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy

Asia Pacific Epilepsy Drugs Market Overview

The Asia Pacific epilepsy drugs market is analysed based on China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. According to the World Health Organization (WHO) report, epilepsy is more common in developing countries than in developed countries, accounting for a prevalence of 6.1% and 5.0%, respectively. China is the most populated country in the world and the one with the most patients with neurological disorders. According to the Centers of Disease Control and Prevention, in China, the prevalence rate of active epilepsy is 0.48% to 8.5%; there are approximately 9 million people with epilepsy in Mainland China, two-thirds of whom are children. ~30% of patients with epilepsy are not capable of controlling their seizures with the AEDs that are currently available in the market; thus, this disease has significant unmet medical needs.

Moreover, the drug approvals in the country are propelling the market growth. For instance, in August 2021, Eisai Co., Ltd. obtained two additional approvals of the antiepileptic drug (AED) Fycompa, as "a monotherapy for partial-onset seizures" and "an adjunctive treatment / a monotherapy for a pediatric indication for partial onset seizures in patients with epilepsy four years of age and older" in China from the National Medical Products Administration.

Asia Pacific Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Epilepsy Drugs Market Segmentation

The Asia Pacific epilepsy drugs market is segmented into treatment, distribution channel, and country.

Based on treatment, the Asia Pacific epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.

In terms of distribution channel, the Asia Pacific epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.

Based on country, the Asia Pacific epilepsy drugs market is segmented China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific epilepsy drugs market in 2022.

Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Asia Pacific epilepsy drugs market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Epilepsy Drugs Market Landscape

• 4.1 Overview

5. Asia Pacific Epilepsy Drugs Market - Key Industry Dynamics

• 5.1 Market Drivers
  • 5.1.1 Growing Prevalence of Epilepsy
  • 5.1.2 Increasing Number of Elderly People
• 5.2 Market Restraints
  • 5.2.1 Recall of Therapeutic Products
• 5.3 Market Opportunities
  • 5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
• 5.4 Future Trends
  • 5.4.1 Increasing Product Approvals
• 5.5 Impact Analysis

6. Epilepsy Drugs Market - Asia Pacific Market Analysis

• 6.1 Overview
• 6.2 Asia Pacific Epilepsy Drugs Market Revenue (US$ Mn), 2022 - 2030

7. Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Treatment

• 7.1 Overview
• 7.2 Asia Pacific Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
• 7.3 First Generation Antiepileptics
  • 7.3.1 Overview
  • 7.3.2 First Generation Antiepileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Second Generation Anti-epileptics
  • 7.4.1 Overview
  • 7.4.2 Second Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• 7.5 Third Generation Anti-epileptics
  • 7.5.1 Overview
  • 7.5.2 Third Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Distribution Channel

• 8.1 Overview
• 8.2 Asia Pacific Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
• 8.3 Hospital Pharmacy
  • 8.3.1 Overview
  • 8.3.2 Hospital Pharmacy: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• 8.4 Retail Pharmacy Stores
  • 8.4.1 Overview
  • 8.4.2 Retail Pharmacy Stores: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• 8.5 Others
  • 8.5.1 Overview
  • 8.5.2 Others: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 - Country Analysis

• 9.1 Asia Pacific Epilepsy Drugs Market, by Key Country- Revenue (2022) (US$ Million)
  • 9.1.1 Asia Pacific Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
    • 9.1.1.1 China: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.1.1 Overview
      • 9.1.1.1.2 China: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.1.3 China: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.1.4 China: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
    • 9.1.1.2 Japan: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.2.1 Overview
      • 9.1.1.2.2 Japan: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.2.3 Japan: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.2.4 Japan: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
    • 9.1.1.3 India: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.3.1 Overview
      • 9.1.1.3.2 India: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.3.3 India: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.3.4 India: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
    • 9.1.1.4 Australia: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.4.1 Overview
      • 9.1.1.4.2 Australia: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.4.3 Australia: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.4.4 Australia: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
    • 9.1.1.5 South Korea: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.5.1 Overview
      • 9.1.1.5.2 South Korea: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.5.3 South Korea: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.5.4 South Korea: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
    • 9.1.1.6 Rest of Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.6.1 Overview
      • 9.1.1.6.2 Rest of Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.6.3 Rest of Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.6.4 Rest of Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Epilepsy Drugs Market-Industry Landscape

• 10.1 Overview
• 10.2 Growth Strategies in the Epilepsy Drugs Market
• 10.3 Inorganic Growth Strategies
  • 10.3.1 Overview
• 10.4 Organic Growth Strategies
  • 10.4.1 Overview

11. Company Profiles

• 11.1 Novartis AG
  • 11.1.1 Key Facts
  • 11.1.2 Business Description
  • 11.1.3 Products and Services
  • 11.1.4 Financial Overview
  • 11.1.5 SWOT Analysis
  • 11.1.6 Key Developments
• 11.2 Pfizer Inc
  • 11.2.1 Key Facts
  • 11.2.2 Business Description
  • 11.2.3 Products and Services
  • 11.2.4 Financial Overview
  • 11.2.5 SWOT Analysis
  • 11.2.6 Key Developments
• 11.3 GSK Plc
  • 11.3.1 Key Facts
  • 11.3.2 Business Description
  • 11.3.3 Products and Services
  • 11.3.4 Financial Overview
  • 11.3.5 SWOT Analysis
  • 11.3.6 Key Developments
• 11.4 Abbott Laboratories
  • 11.4.1 Key Facts
  • 11.4.2 Business Description
  • 11.4.3 Products and Services
  • 11.4.4 Financial Overview
  • 11.4.5 SWOT Analysis
  • 11.4.6 Key Developments
• 11.5 Sanofi SA
  • 11.5.1 Key Facts
  • 11.5.2 Business Description
  • 11.5.3 Products and Services
  • 11.5.4 Financial Overview
  • 11.5.5 SWOT Analysis
  • 11.5.6 Key Developments
• 11.6 Teva Pharmaceutical Industries Ltd
  • 11.6.1 Key Facts
  • 11.6.2 Business Description
  • 11.6.3 Products and Services
  • 11.6.4 Financial Overview
  • 11.6.5 SWOT Analysis
  • 11.6.6 Key Developments
• 11.7 Alkem Laboratories Ltd
  • 11.7.1 Key Facts
  • 11.7.2 Business Description
  • 11.7.3 Products and Services
  • 11.7.4 Financial Overview
  • 11.7.5 SWOT Analysis
  • 11.7.6 Key Developments

12. Appendix

• 12.1 About Us
• 12.2 Glossary of Terms

List Of Tables

• Table 1. Asia Pacific Epilepsy Drugs Market Segmentation
• Table 2. China: Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
• Table 3. China: Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
• Table 4. Japan: Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
• Table 5. Japan: Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
• Table 6. India: Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
• Table 7. India: Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
• Table 8. Australia: Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
• Table 9. Australia: Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
• Table 10. South Korea: Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
• Table 11. South Korea: Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
• Table 12. Rest of Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
• Table 13. Rest of Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
• Table 14. Recent Inorganic Growth Strategies in the Epilepsy Drugs Market
• Table 15. Recent Organic Growth Strategies in the Asia Pacific Epilepsy Drugs Market
• Table 16. Glossary of Terms, Asia Pacific Epilepsy Drugs Market

List Of Figures

• Figure 1. Asia Pacific Epilepsy Drugs Market Segmentation, By Country
• Figure 2. Asia Pacific Epilepsy Drugs Market: Key Industry Dynamics
• Figure 3. Asia Pacific Epilepsy Drugs Market: Impact Analysis of Drivers and Restraints
• Figure 4. Asia Pacific Epilepsy Drugs Market Revenue (US$ Mn), 2022 - 2030
• Figure 5. Asia Pacific Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
• Figure 6. First Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 7. Second Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 8. Third Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 9. Asia Pacific Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
• Figure 10. Hospital Pharmacy: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 11. Retail Pharmacy Stores: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 12. Others: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 13. Asia Pacific Epilepsy Drugs Market, by Key Country - Revenue (2022) (US$ Million)
• Figure 14. Asia Pacific Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
• Figure 15. China: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 16. Japan: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 17. India: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 18. Australia: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 19. South Korea: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 20. Rest of Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 21. Growth Strategies in the Epilepsy Drugs Market